Equities

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Actions
  • Price (EUR)32.14
  • Today's Change0.00 / 0.00%
  • Shares traded109.00
  • 1 Year change-28.59%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments351552701
Total Receivables, Net2242910
Total Inventory1468616
Prepaid expenses393625
Other current assets, total5.471672
Total current assets766720824
Property, plant & equipment, net212526
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets1.311632
Total assets789760882
LIABILITIES
Accounts payable383717
Accrued expenses134101107
Notes payable/short-term debt000
Current portion long-term debt/capital leases76307.58
Other current liabilities, total------
Total current liabilities248168132
Total long term debt333408534
Total debt409438542
Deferred income tax------
Minority interest------
Other liabilities, total141417
Total liabilities594590683
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital3,0362,4801,857
Retained earnings (accumulated deficit)(2837)(2309)(1657)
Treasury stock - common------
Unrealized gain (loss)(0.97)1.650.00
Other equity, total(2.57)(2.52)(2.09)
Total equity195170199
Total liabilities & shareholders' equity789760882
Total common shares outstanding12011198
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.